The warburg effect and the hallmarks of cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 17, Issue 2, 2017, Pages 164-170

  Schwartz, Laurent ^a   Supuran, Claudiu T ^b   Alfarouk, Khalid O ^c,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Al Ghad International Colleges for Applied Medical Sciences   (Saudi Arabia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alpha lipo c acid; ATP; Metabolic treatment; Unification theory; Warburg s effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBON DIOXIDE; CARBONATE DEHYDRATASE; CARBONIC ACID; COLLAGEN; CYTOKINE; GROWTH FACTOR; HYDROXYCITRIC ACID; LACTIC ACID; THIOCTIC ACID; CITRIC ACID; GLUCOSE;

ACIDITY; ACIDOSIS; ALKALOSIS; ANAEROBIC GLYCOLYSIS; BIOSYNTHESIS; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; CELL PROLIFERATION; CHEMOTHERAPY; GLUCOSE TRANSPORT; HEXOSE MONOPHOSPHATE SHUNT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MALIGNANT NEOPLASM; METABOLIC ACTIVITY ASSAY; METABOLOMICS; MITOCHONDRION SWELLING; ONCOGENE; OXIDATIVE PHOSPHORYLATION; REVIEW; TUMOR INVASION; UPREGULATION; WARBURG EFFECT; ANIMAL; GLYCOLYSIS; METABOLISM; MITOCHONDRION; NEOPLASM; PATHOLOGY; PENTOSE PHOSPHATE CYCLE;

ACIDOSIS; ADENOSINE TRIPHOSPHATE; ALKALOSIS; ANIMALS; CARBON DIOXIDE; CELL PROLIFERATION; CITRATES; GLUCOSE; GLYCOLYSIS; HUMANS; MITOCHONDRIA; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE PATHWAY; THIOCTIC ACID;

EID: 85011076202     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520616666161031143301     Document Type: Review

References (108)

1. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
2. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144, 646-674.
3. Wang, E.; Zaman, N.; Mcgee, S.; Milanese, J.S.; Masoudi-Nejad, A.; O’Connor-McCourt, M. Predictive genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin. Cancer Biol., 2015, 30, 4-12.
4. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
5. Pavlides, S.; Vera, I.; Gandara, R.; Sneddon, S.; Pestell, R.G.; Mercier, I.; Martinez-Outschoorn, U.E.; Whitaker-Menezes, D.; Howell, A.; Sotgia, F.; Lisanti, M.P. Warburg meets autophagy: Cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy and aerobic glycolysis. Antioxid. Redox. Signal., 2012, 16, 1264-1284.
6. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 2009, 324, 1029-1033.
7. Maurice Israel, L.S. Cancer: A dysmethylation syndrome?. John Libbey Eurotext, 2005.
8. Seyfried, T.N.; Shelton, L.M. Cancer as a metabolic disease. Nutr. Metab. (Lond), 2010, 7, 7.
9. Israël, M.; Schwartz, L. The metabolic advantage of tumor cells. Mol. Cancer, 2011, 10, 70.
10. Mazurek, S.; Boschek, C.B.; Hugo, F.; Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol., 2005, 15, 300-308.
11. Neumann, C.; Boubakari; Grünert, R.; Bednarski, P.J. Nicotinamide adenine dinucleotide phosphate-regenerating system coupled to a glutathione-reductase microtiter method for determination of total glutathione concentrations in adherent growing cancer cell lines. Anal. Biochem., 2003, 320, 170-178.
12. Ganea, E.; Harding, J.J. Glutathione-related enzymes and the eye. Curr. Eye Res., 2006, 31, 1-11.
13. Ying, W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences. Antioxid. Redox. Signal., 2008, 10, 179-206.
14. Alfarouk, K.O. Tumor metabolism, cancer cell transporters, and microenvironmental resistance. J. Enzyme Inhib. Med. Chem., 2016, 1-8.
15. Warburg, O. On the formation of lactic acid with growth. Biochem. Z, 1925, 160, 307-311.
16. Reshkin, S.J.; Bellizzi, A.; Caldeira, S.; Albarani, V.; Malanchi, I.; Poignee, M.; Alunni-Fabbroni, M.; Casavola, V.; Tommasino, M. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J., 2000, 14, 2185-2197.
17. Alfarouk, K. O.; Verduzco, D.; Rauch, C.; Muddathir, A. K.; Adil, H. H. B.; Elhassan, G. O.; Ibrahim, M. E.; David Polo Orozco, J.; Cardone, R. A.; Reshkin, S. J.; Harguindey, S. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience, 2014, 1, 777-802.
18. Roskelley, R. C.; Mayer, N.; Horwitt, B. N.; Salter, W. T. Studies in cancer. vii. Enzyme deficiency in human and experimental cancer. J. Clin. Invest., 1943, 22, 743-751.
19. López-Lázaro, M. The warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer. Agents Med. Chem., 2008, 8, 305-312.
20. Seyfried, T. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer; 1st ed.; 2012.
21. D’Agostino, D.M.; Bernardi, P.; Chieco-Bianchi, L.; Ciminale, V. Mitochondria as functional targets of proteins coded by human tumor viruses. Adv. Cancer Res., 2005, 94, 87-142.
22. Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer, 2006, 118, 3030-3044.
23. Clippinger, A.J.; Bouchard, M.J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J. Virol., 2008, 82, 6798-6811.
24. Koike, K. Hepatitis B Virus X gene is implicated in liver carcinogenesis. Cancer Lett., 2009, 286, 60-68.
25. Pacini, N.; Borziani, F. Cancer stem cell theory and the Warburg effect, two sides of the same coin? Int. J. Mol. Sci., 2014, 15, 8893-8930.
26. Seyfried, T.N.; Flores, R.E.; Poff, A.M.; D’Agostino, D.P. Cancer as a metabolic disease: Implications for novel therapeutics. Carcinogenesis, 2014, 35, 515-527.
27. Ortega, A.D.; Sánchez-Aragó, M.; Giner-Sánchez, D.; Sánchez-Cenizo, L.; Willers, I.; Cuezva, J.M. Glucose avidity of carcinomas. Cancer Lett., 2009, 276, 125-135.
28. Da Veiga Moreira, J.; Peres, S.; Steyaert, J.M.; Bigan, E.; Paulevé, L.; Nogueira, M. L.; Schwartz, L. Cell cycle progression is regulated by intertwined redox oscillators. Theor. Biol. Med. Model., 2015, 12, 10.
29. Alfarouk, K.O.; Muddathir, A.K.; Shayoub, M.E.A. Tumor acidity as evolutionary spite. Cancers (Basel). 2011, 3, 408-414.
30. Gatenby, R.A.; Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer, 2008, 8, 56-61.
31. Webb, B.A.; Chimenti, M.; Jacobson, M.P.; Barber, D.L. Dysregulated pH: A perfect storm for cancer progression. Nat. Rev. Cancer, 2011, 11, 671-677.
32. Lee, C.H.; Cragoe, E.J.; Edwards, A.M. Control of hepatocyte DNA synthesis by intracellular pH and its role in the action of tumor promoters. J. Cell. Physiol., 2003, 195, 61-69.
33. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov., 2011, 10, 767-77.
34. Rofstad, E.K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res., 2006, 66, 6699-6707.
35. Cardone, R.A.; Casavola, V.; Reshkin, S.J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer, 2005, 5, 786-795.
36. Huber, V.; De Milito, A.; Harguindey, S.; Reshkin, S. J.; Wahl, M. L.; Rauch, C.; Chiesi, A.; Pouysségur, J.; Gatenby, R.A.; Rivoltini, L.; Fais, S. Proton dynamics in cancer. J. Transl. Med., 2010, 8, 57.
37. Kato, Y.; Lambert, C.A.; Colige, A.C.; Mineur, P.; Noël, A.; Frankenne, F.; Foidart, J.-M.; Baba, M.; Hata, R.-I.; Miyazaki, K.; Tsukuda, M. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling. J. Biol. Chem., 2005, 280, 10938-10944.
38. Montcourrier, P.; Mangeat, P.H.; Salazar, G.; Morisset, M.; Sahuquet, A.; Rochefort, H. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res., 1990, 50, 6045-6054.
39. Lou, Y.; McDonald, P.C.; Oloumi, A.; Chia, S.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.; Leung, S.; Huntsman, D.; Clarke, B.; Sutherland, B.W.; Waterhouse, D.; Bally, M.; Roskelley, C.; Overall, C.M.; Minchinton, A.; Pacchiano, F.; Carta, F.; Scozzafava, A.; Touisni, N.; Winum, J.Y.; Supuran, C.T.; Dedhar, S. Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res., 2011, 71, 3364-3376.
40. Supuran, C.T. How many carbonic anhydrase inhibition mechanisms exist? J. Enzyme Inhib. Med. Chem., 2016, 31, 345-360.
41. Karagiannis, J.; Young, P.G. Intracellular pH homeostasis during cell-cycle progression and growth state transition in Schizosaccharomyces pombe. J. Cell Sci., 2001, 114, 2929-2941.
42. Racker, E. Bioenergetics and the problem of tumor growth. Am. Sci., 60, 56-63.
43. Lu, X.; Qin, W.; Li, J.; Tan, N.; Pan, D.; Zhang, H.; Xie, L.; Yao, G.; Shu, H.; Yao, M.; Wan, D.; Gu, J.; Yang, S. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res., 2005, 65, 6843-6849.
44. Spugnini, E.P.; Citro, G.; Fais, S. Proton pump inhibitors as anti 8vacuolar-ATPases drugs: A novel anticancer strategy. J. Exp. Clin. Cancer Res., 2010, 29, 44.
45. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov., 2008, 7, 168-181.
46. Fais, S.; De Milito, A.; You, H.; Qin, W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res., 2007, 67, 10627-10630.
47. Gillies, R.J.; Martinez-Zaguilan, R.; Martinez, G.M.; Serrano, R.; Perona, R. Tumorigenic 3T3 cells maintain an alkaline intracellular pH under physiological conditions. Proc. Natl. Acad. Sci. USA, 1990, 87, 7414-7418.
48. Moolenaar, W.H. Effects of growth factors on intracellular pH regulation. Annu. Rev. Physiol., 1986, 48, 363-376.
49. Simon, S.; Roy, D.; Schindler, M. Intracellular pH and the control of multidrug resistance. Proc. Natl. Acad. Sci. USA, 1994, 91, 1128-1132.
50. Pouysségur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006, 441, 437-443.
51. Alfarouk, K.O.; Stock, C.M.; Taylor, S.; Walsh, M.; Muddathir, A.K.; Verduzco, D.; Bashir, A.H.H.; Mohammed, O.Y.; Elhassan, G.O.; Harguindey, S.; Reshkin, S.J.; Ibrahim, M. E.; Rauch, C. Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell Int. 2015, 15, 71.
52. Cosentini, E.; Haberl, I.; Pertschy, P.; Teleky, B.; Mallinger, R.; Baumgartner, G.; Wenzl, E.; Hamilton, G. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. Int. J. Oncol., 2001, 19, 1069-1074.
53. Hofer, K.G.; Mivechi, N.F. Tumor cell sensitivity to hyperthermia as a function of extracellular and intracellular pH. J. Natl. Cancer Inst., 1980, 65, 621-625.
54. Harguindey, S.; Henderson, E.S.; Naeher, C. Effects of systemic acidification of mice with Sarcoma 180. Cancer Res., 1979, 39, 4364-4371.
55. Harguindey, S.; Orive, G.; Luis Pedraz, J.; Paradiso, A.; Reshkin, S.J. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature. Biochim. Biophys. Acta, 2005, 1756, 1-24.
56. Schwartz, L.; Coldwell, D. Is Liver disease caused by increased pressure? Interstitial pressure as a causative mechanism in carcinogenesis and in the differential blood supply in liver tumors from the hepatic artery. J. Liver, 2014, 3.
57. Fleury, V.; Schwartz, L. Numerical investigation of the effect of loss of cellular polarity on cancer invasiveness and geometry. Fractals, 2003, 11, 397-414.
58. Baish, J.W.; Jain, R.K. Fractals and cancer. Cancer Res., 2000, 60, 3683-3688.
59. Tan, D.S.; Potts, H.W.; Leong, A.C.; Gillett, C.E.; Skilton, D.; Harris, W.H.; Liebmann, R.D.; Hanby, A.M. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J. Pathol., 1999, 189, 20-27.
60. Schwartz, L. Cancer-Between glycolysis and physical constraint. In Cancer-Between Glycolysis and Physical Constraint; Springer Berlin Heidelberg: Berlin, Heidelberg, 2004; pp 107-116.
61. Schwartz, L.; Guais, A.; Pooya, M.; Abolhassani, M. Is inflammation a consequence of extracellular hyperosmolarity? J. Inflamm. (Lond). 2009, 6, 21.
62. Casselton, P.J.; Stacey, J.L. Observations on the nitrogen metabolism of prototheca kruger. New Phytol. 1969, 68, 731-749.
63. Levy Nogueira, M.; Da Veiga Moreira, J.; Baronzio, G. F.; Dubois, B.; Steyaert, J.M.; Schwartz, L. Mechanical stress as the common denominator between chronic inflammation, cancer, and Alzheimer’s disease. Front. Oncol., 2015, 5, 197.
64. Schwartz, L.M.; Israël, I.P. Inflammation and Carcinogenesis: A change in the metabolic process. In Cancer Microenvironment and Therapeutic Implications; Baronzio, G.; Fiorentini, G.; Cogle, C. R., Eds.; Springer Netherlands: Dordrecht, 2009; pp 3-18.
65. Abolhassani, M.; Wertz, X.; Pooya, M.; Chaumet-Riffaud, P.; Guais, A.; Schwartz, L. Hyperosmolarity causes inflammation through the methylation of protein phosphatase 2A. Inflamm. Res., 2008, 57, 419-29.
66. Runyon, B. A. Malignancy-related ascites and ascitic fluid “humoral tests of malignancy”. J. Clin. Gastroenterol., 1994, 18, 94-98.
67. Szturmowicz, M.; Tomkowski, W.; Fijalkowska, A.; Burakowski, J.; Sakowicz, A.; Filipecki, S. The role of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) evaluation in pericardial fluid for the recognition of malignant pericarditis. Int. J. Biol., Markers, 12, 96-101.
68. Blake, G.J.; Ridker, P.M. Inflammatory bio-markers and cardiovascular risk prediction. J. Intern. Med. 2002, 252, 283-294.
69. Sipe, J.D. Acute-phase proteins in osteoarthritis. Semin. Arthritis Rheum., 1995, 25, 75-86.
70. St Clair, E.W. Tides of inflammation: Impact of biologics. J. Rheumatol. Suppl., 2002, 65, 22-26.
71. Montón, C.; Torres, A. Lung inflammatory response in pneumonia. Monaldi. Arch. Chest Dis., 1998, 53(1), 56-63.
72. Sadoshima, J.; Izumo, S. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: Potential involvement of an autocrine/paracrine mechanism. EMBO J., 1993, 12, 1681-1692.
73. Yamazaki, T.; Komuro, I.; Yazaki, Y. Molecular mechanism of cardiac cellular hypertrophy by mechanical stress. J. Mol. Cell. Cardiol., 1995, 27, 133-140.
74. Wu, M.; Frieboes, H.B.; McDougall, S.R.; Chaplain, M.A.J.; Cristini, V.; Lowengrub, J. The effect of interstitial pressure on tumor growth: Coupling with the blood and lymphatic vascular systems. J. Theor. Biol., 2013, 320, 131-151.
75. Fleury, V.; Schwartz, L. Diffusion limited aggregation from shear stress as a simple model of vasculogenesis. Fractals, 1999, 7, 33-39.
76. Alfarouk, K.O.; Ibrahim, M.E.; Gatenby, R.A.; Brown, J.S. Riparian ecosystems in human cancers. Evol. Appl., 2013, 6, 46-53.
77. Chang, Y.S.; di Tomaso, E.; McDonald, D.M.; Jones, R.; Jain, R. K.; Munn, L.L. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. USA, 2000, 97, 14608-14613.
78. Danciu, T.E.; Gagari, E.; Adam, R.M.; Damoulis, P.D.; Freeman, M.R. Mechanical strain delivers anti-apoptotic and proliferative signals to gingival fibroblasts. J. Dent. Res., 2004, 83, 596-601.
79. Wang, X.; Yu, W.; Zheng, L. The dynamics of NF-κB pathway regulated by circadian clock. Math. Biosci., 2015, 260, 47-53.
80. Lardner, A. The effects of extracellular pH on immune function. J. Leukoc. Biol., 2001, 69, 522-530.
81. Husain, Z.; Huang, Y.; Seth, P.; Sukhatme, V.P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid- derived suppressor cells and NK cells. J. Immunol., 2013, 191, 1486-1495.
82. Alfarouk, K.O.; Shayoub, M.E.A.A.; Muddathir, A.K.; Elhassan, G.O.; Bashir, A.H.H.H. Evolution of tumor metabolism might reflect carcinogenesis as a reverse evolution process (Dismantling of Multicellularity). Cancers (Basel)., 2011, 3, 3002-3017.
83. Padma, M.V; Said, S.; Jacobs, M.; Hwang, D.R.; Dunigan, K.; Satter, M.; Christian, B.; Ruppert, J.; Bernstein, T.; Kraus, G.; Mantil, J.C. Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol., 2003, 64, 227-237.
84. Singh, D.; Miles, K. Multiparametric PET/CT in oncology. Cancer Imaging, 2012, 12, 336-344.
85. Elliott, R.; Barnett, B. Ultrastructural observation of mitochondria in human breast carcinoma cells. Microsc. Microanal., 2011, 17, 194-195.
86. Riganti, C.; Gazzano, E.; Polimeni, M.; Aldieri, E.; Ghigo, D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic. Biol. Med., 2012, 53, 421-436.
87. Keizer, H.G.; Pinedo, H.M.; Schuurhuis, G.J.; Joenje, H. Doxorubicin (adriamycin): A critical review of free radical- dependent mechanisms of cytotoxicity. Pharmacol. Ther., 1990, 47, 219-231.
88. Guénin, S.; Schwartz, L.; Morvan, D.; Steyaert, J.M.; Poignet, A.; Madelmont, J.C.; Demidem, A. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: A mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int. J. Oncol., 2008, 32, 49-57.
89. Liang, X.J.; Finkel, T.; Shen, D.W.; Yin, J.J.; Aszalos, A.; Gottesman, M.M. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol. Cancer Res., 2008, 6, 1499-506.
90. Wallace, K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc. Toxicol., 2007, 7, 101-107.
91. Cullen, K.J.; Yang, Z.; Schumaker, L.; Guo, Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr., 2007, 39, 43-50.
92. Matsuyama, S.; Xu, Q.; Velours, J.; Reed, J.C. The mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol. Cell, 1998, 1, 327-336.
93. Leduc, E.H.; Wilson, J.W. Effect of essential fatty acid deficiency on ultrastructure and growth of transplantable mouse hepatoma BRL. J. Natl. Cancer Inst., 1964, 33, 721-739.
94. Henry-Mowatt, J.; Dive, C.; Martinou, J.C.; James, D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene, 2004, 23, 2850-2860.
95. Wang, P.; Xu, C.; Xia, X.; Xu, J.; Wang, X.; Xiang, J.; Leung, A. W. Mitochondrial damage in nasopharyngeal carcinoma cells induced by ultrasound radiation in the presence of hypocrellin B. J. Ultrasound Med., 2010, 29, 43-50.
96. Michelakis, E.D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T.L.; Mackey, J. R.; Fulton, D.; Abdulkarim, B.; McMurtry, M.S.; Petruk, K.C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med., 2010, 2, 31ra34.
97. Schwartz, L.; Abolhassani, M.; Guais, A.; Sanders, E.; Steyaert, J. M.; Campion, F.; Israël, M. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol. Rep., 2010, 23, 1407-1416.
98. Schwartz, L.; Guais, A.; Israël, M.; Junod, B.; Steyaert, J.M.; Crespi, E.; Baronzio, G.; Abolhassani, M. Tumor regression with a combination of drugs interfering with the tumor metabolism: Efficacy of hydroxycitrate, lipoic acid and capsaicin. Invest. New Drugs, 2013, 31, 256-264.
99. Abolhassani, M.; Guais, A.; Sanders, E.; Campion, F.; Fichtner, I.; Bonte, J.; Baronzio, G.; Fiorentini, G.; Israël, M.; Schwartz, L. Screening of well-established drugs targeting cancer metabolism: Reproducibility of the efficacy of a highly effective drug combination in mice. Invest. New Drugs, 2012, 30, 1331-1342.
100. Zachar, Z.; Marecek, J.; Maturo, C.; Gupta, S.; Stuart, S.D.; Howell, K.; Schauble, A.; Lem, J.; Piramzadian, A.; Karnik, S.; Lee, K.; Rodriguez, R.; Shorr, R.; Bingham, P.M. Non-redox- active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents In vivo. J. Mol. Med. (Berl)., 2011, 89, 1137-1148.
101. Baronzio, G.; Schwartz, L.; Crespi, E.; Guais, A.; Sanders, E.; Delépine, N.; Fiorentini, G. Early clinical and toxicological results of a combination of natural glycolysis inhibitors (METABLOCTM) on cancer patients. Biomed. Res., 2012, 23, 219-222.
102. Schwartz, L.; Buhler, L.; Icard, P.; Lincet, H.; Steyaert, J.M. Metabolic treatment of cancer: Intermediate results of a prospective case series. Anticancer Res., 2014, 34, 973-980.
103. Schwartz, L.; Buhler, L.; Icard, P.; Lincet, H.; Summa, G.M.; Steyaert, J.M. Metabolic cancer treatment: Intermediate results of a clinical study. Cancer Ther., 2014, 10, 13-19.
104. Schwartz, L.; Gabillet, J.; Buhler, L.; Steyaert, J.M. The addition of chloroquine and metformine to Metabloc induces a rapid drop of tumor markers in advanced carcinoma. Cancer Ther., 2014, 10, 20-27.
105. Elliott, R.L.; Jiang, X.P.; Head, J.F. Mitochondria organelle transplantation: Introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity. Breast Cancer Res. Treat., 2012, 136, 347-354.
106. Kaipparettu, B.A.; Ma, Y.; Park, J.H.; Lee, T.L.; Zhang, Y.; Yotnda, P.; Creighton, C.J.; Chan, W.Y.; Wong, L.J.C. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. PLoSOne, 2013, 8, e61747.
107. Pino-Barrio, M.J.; García-García, E.; Menéndez, P.; Martínez-Serrano, A. V-myc immortalizes human neural stem cells in the absence of pluripotency-associated traits. PLoSOne, 2015, 10, e0118499.
108. Page, S.; Salem, M.; Laughlin, M.R. Intracellular Mg2+ regulates ADP phosphorylation and adenine nucleotide synthesis in human erythrocytes. Am. J. Physiol., 1998, 274, E920-E927.